Search Studies
Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.
-
Testing the Impact of COVID-19 on Taste and Smell
Official Title Short-term and long-term impact of COVID-19 on multiple sensory systemsPurpose
Aim 1. To learn about how COVID-19 impacts the senses
We will study how COVID-19 influences basic senses including smell, taste, and balance. We will also administer health questionnaires and cognitive tests to determine how a past COVID-19 infection may influence current health.
Aim 2. To learn about how sensory problems may change and recover over time
We track people with COVID-19 and other infections over time to determine if sensory related symptoms improve. This includes three total follow up visits after the initial assessment.
Our overall goal is to better understand how COVID-19 influences sensory systems over time.
Could this study be right for you?
- Have had COVID-19 or an upper respiratory infection (such as the common cold or flu) within the last 8 weeks, OR
- Had COVID-19 or an upper respiratory infection >8 weeks ago with ongoing sensory symptoms (smell, taste, hearing or balancing problems, dizziness).
Age Range
18 - 99 years -
Understanding the Link Between Chronic Pain and Suicide Risk
Official Title Modifiable Mechanisms Linking Chronic Pain to Suicide RiskPurpose
The purpose of this study is to better understand how certain thoughts, feelings, and responses to pain may be related to thoughts of suicide in people with chronic pain.
Participants will complete an online screening session that will involve a short interview and questionnaires which will take approximately 3.5 hours and a 2.5-hour in-person lab visit that will include EMG and EEG and a pain pressure test. After, participants will be asked to complete daily app-based questionnaires on their phone for 21 days.
Could this study be right for you?
- Currently experiencing chronic pain
- Have recently felt that life is not worth living or that you would be better off dead
Age Range
18 - 65 years -
The OSU Sleep Study - An Online Parent Training Research Study for Insomnia/Sleep Problems in Young Children with Autism Spectrum Disorder
Official Title A Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic ChildrenPurpose
Insomnia is a common problem for young children with autism spectrum disorder (ASD) and their families. The purpose of this study is to compare the benefits of sleep parent training (SPT) program to a structured parent education program (SPE) for insomnia improvement in young children with autism spectrum disorder.
Could this study be right for you?
You may be eligible if your child:
1. Has a diagnosis of Autism Spectrum Disorder
2. Has significant Sleep Disturbance
3. Is free of a significant health problem
4. Is on stable medication
Age Range
3 - 7 years -
Emotional Regulation among Distressed Young Adults
Official Title Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Distressed Young Adults: A Single-Session DesignPurpose
This study looks at how learning to manage emotions can improve your mental and physical health.
You will meet with a research team member for an interview about your mental health. If you qualify, we will take a few drops of blood from a finger prick and check your heart rate and blood pressure. You will also learn some emotional regulation skills for handling tough emotions and fill out surveys about yourself. For two weeks after, you'll answer short surveys on your phone five times a day. Then you'll come back for one more short visit.
Could this study be right for you?
-
Have a depressive or anxiety disorder
-
Are not currently receiving mental health counseling
-
Read and understand English
-
Are willing to have a finger prick for a blood sample
-
Free from immune-related or heart-related diseases
-
Own or have access to a smartphone
Age Range
18 - 39 years -
-
Anxiety and Inflammation in Adults
Official Title Inflammation in adults with anxiety disordersPurpose
This study looks at how anxiety can affect your immune health.
You will meet with a research team member for an interview about your mental health. If you qualify, we will take a few drops of blood from a finger prick. Then you will fill out some surveys about yourself and your mental health.
Study visits will last approximately 2 hours. Once the 2-hour visit is complete, you will be released from the study. There will be no long-term follow-up after completion of research related procedures.
Could this study be right for you?
-
Have an anxiety disorder (social anxiety disorder, specific phobia, panic disorder, agoraphobia, generalized anxiety disorder).
-
Are 18 years or older
-
Read and understand English
-
Free from immune-related diseases
Age Range
18 years and up -
-
Effectiveness of Pairing a Keto Diet with Psychotherapy for PTSD
Official Title Enhancing PTSD Recovery with Metabolic-Augmented PsychotherapyPurpose
To test whether a personalized ketogenic program in combination with cognitive processing therapy (CPT) can improve symptoms of post-traumatic stress disorder (PTSD).
The study will involve 11 weeks of a personalized ketogenic program guided by a dietician, 10 sessions of CPT, interviews, questionnaires, and wearing sensors to track your stress, sleep, glucose, and ketones.
Could this study be right for you?
- 18 years or older
- Able to attend in-person visits to OSU once per week for 12 weeks
- Meet diagnostic criteria for PTSD (prior diagnosis is NOT required, all individuals will be evaluated by the study team)
Age Range
18 years and up -
Single-Dose Investigational Drug Study for Depression and Anxiety
Official Title A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants with Major Depressive Disorder (MDD) and Moderate to Severe AnxietyPurpose
The aim of this study is to determine the effects of one administration of the psychedelic compound CYB003 on depression and anxiety symptoms as well as its effects on brain function.
Could this study be right for you?
1. Currently have depression with moderate to severe anxiety
2. Are currently taking an antidepressant and your symptoms have not improved enough
3. Have been on the same antidepressant dose for about 1 month
Age Range
21 - 65 years -
EEG Research Study
Official Title Neural Biomarkers of Sensory Symptoms in AutismPurpose
This research aims to understand how sensory issues, particularly related to hearing, impact children on the autism spectrum. Using a tool called EEG, we study how their brains respond to sounds. Previous research with adults on the spectrum showed that their brains react more slowly to sounds, affecting their ability to pay attention. This protocol investigates if a similar pattern exists in children with autism.
Could this study be right for you?
We are searching for healthy neurotypical boys aged 8-12.
Age Range
8 - 12 years -
A Study about how virtual Yoga sessions affect symptoms and quality of life in patients with diabetic gastroparesis
Official Title The Effect of Virtual Yoga Intervention on Symptom Severity and Quality of Life in Patients with Diabetic GastroparesisPurpose
The purpose of this research study is to understand how virtual Yoga sessions conducted 4 days a week for 12 weeks affect digestive symptoms and quality of life in those suffering from gastroparesis due to diabetes mellitus.
Could this study be right for you?
- Able to understand English
- Must have been diagnosed with gastroparesis
- Must have type 1 or type 2 diabetes mellitusAge Range
18 - 65 years -
Clinical Trial Involving Monthly Injections for Osteogenesis Imperfecta (OI)
Official Title A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)Purpose
The reason for this study is to see if the investigational drug, called AGA2115, can help increase bone mineral density in people with osteogenesis imperfecta. AGA2115 or a placebo drug will be given at the clinic once a month subcutaneously. During this study, changes in bone biomarkers, number of bone fractures, and quality of life, will be measured to see if AGA2115 can help people with osteogenesis imperfecta. This study will also look at how the body absorbs, breaks down and gets rid of AGA2115 (called pharmacokinetics), if AGA2115 affects any markers of bone metabolism in the body, if the body’s natural defense system (the immune system) tries to make antibodies to AGA2115 (called immunogenicity) and how well people feel while taking AGA2115, including any side effects they may have.
You will be asked to complete the following: perform monthly injections, take Vitamin D and Calcium supplements, perform ECGs and DEXA scans, provide blood samples, perform grip strength tests, do hearing tests (called Audiometry and Tympanometry), complete questionnaires, undergo a one-time bone biopsy, and see the study doctor.
If you do not have genetic confirmation of osteogenesis imperfecta, we may be able to test for it through the study.
The study will last 27 months.
Could this study be right for you?
The most important eligibility criteria include the following. This is not an expansive list.
- Genetic confirmation of Osteogenesis Imperfecta Type I, III, or IV diagnosis
- DXA scan assessing L1-L4 region
- BMD T-score <= -1.0 at lumber spine OR total hip OR femoral neck
- Cannot be taking IV or oral bisphosphonate with the past 6 months
Age Range
18 - 75 years -
Heart2Heart Research Study
Official Title Creating a Mobile Health Program for Teens with Congenital Heart Disease (“Heart2Heart Research Study”)Purpose
The study aims to understand what teens with congenital heart disease want and need in mobile health program that helps them learn about their heart health and overall wellness.
Could this study be right for you?
Enrollment is by invitation only. The study team will contact you if you are eligible to participate.
Age Range
12 - 18 years -
"Debio-4126" for patients with Acromegaly currently taking octreotide ("Sandostatin" or "Mycapssa") or lanreotide ("Somatuline") with Dr. Luma Ghalib, MD.
Official Title "A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs"Purpose
The purpose of this trial is to see if the study medication "Debio-4126" can safely maintain a low level of growth hormone ("GH") and insulin-like growth factor 1 ("IGF‑1") lab values for patients diagnosed with Acromegaly.
You will be asked to come to visits 1-2 times a month and receive an injection every 12 weeks at our clinic.
At clinic visits, you will be asked to answer questions about your medical history, speak to the study doctor, provide blood and urine samples, do ECGs and other imaging techniques, receive the study medication, and complete questionnaires. Not all of these will be done at every visit. Visits will take place at Outpatient Care East.
This study will use a computer to randomly assign you to the study medication ("Debio-4126") or a placebo, which has no therapeutic effect on the body, commonly referred to as a "sugar pill".
You have 5 chances out of 7 of receiving the study medication.If you are assigned the placebo, you will have a chance to receive the study medication later in the study.
If you are eligible, your participation in this trial will last between 10 to 29 months depending on whether the trial drug is safe and works for you.
If you have any questions about this study, please don't hesitate to reach out to Hangil at 614-814-0809 or email at hangil.kim@osumc.edu.
Could this study be right for you?
Most Important Eligibility Criteria
- Over the age of 18 years old
- Have an official Acromegaly diagnosis
- Currently taking Octreotide or Lanreotide (ex. "Sandostatin", "Mycapssa", "Somatuline", etc...) at any dose for 6 months and on the same dose for the past 3 months.
- Controlled IGF-1 lab values
- Must not have had radiation on pituitary gland in the past
- Must not currently be taking pasireotide (Signifor), pegvisomant (Somavert), or dopamine agonists (Cabergoline)
Age Range
18 - 75 years - Over the age of 18 years old